

ADDRESSOGRAPH, or

Name: DoB:

Hospital number:

CHI:

INGESTION OF A THERAPEUTIC EXCESS OF PARACETAMOL

(ingestions of excessive paracetamol with intent to treat pain or fever and without self – harm intent)

Patients < 16 years

NHS Borders

This care pathway includes the Scottish and Newcastle Antiemetic Pretreatment (SNAP) based regimen for acetylcysteine and is **ONLY** for use in the Emergency department or ward 15, Borders General Hospital.

This version is not available on TOXBASE. For advice contact the on-call toxicologist at the RIE (Monday –Friday 9am-5pm) or the National Poisons Information Service (NPIS) out of hours.

There are 5 different care pathway documents for paracetamol overdose in patients <16 years, please ensure the correct document is used.

Review date January 2022

ADDRESSOGRAPH, or	
Name: DoB: Hospital number: CHI:	

Expected length of stay: approx 24 hours

To be initiated once an INGESTION OF THERAPEUTIC EXCESS OF PARACETAMOL is suspected

(ingestions of excessive paracetamol with intent to treat pain or fever, without self- harm intent)

KEY TO INITIALS OF <u>ALL</u> STAFFCOMPLETING THIS CARE PATHWAY						
Print name	Designation	Initials	Signature	Date		
1						
-						
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						

STAFF: Should be completed in addition to the Clerking notes, PEWS observation chart, infusion charts, prescription & administration record

NHS BORDERS

	Initials & time
SUMMARY	
Reason for the ingestion of a therapeutic excess of paracetamol	
Were the patients/carers aware of the correct therapeutic dose of paracetamol? Yes \square	No □
If yes, why was an excess ingested?	
Therapeutic excess ingested from DateImeIme	
Last dose ingested DateTime	
List all drugs ingested (including brand names ie Lemsip) and the quantity of each	
Total paracetamol ingestedg overhours/days	
CALCULATE:	
Total paracetamol ingested (in any 24- hour period)	, , , , , , , , , , , , , , , , , , ,
mg Patient's weightkg Amount ingested	
Comments	
For obese patients weighing more than 110 kg, the toxic dose in mg/kg should be calculated	ulated using
110 kg, rather than the patient's actual weight.	Jialeu usiriy
110 kg, rather than the patient's actual weight.	
The National Poisons Information Service advises that the child's actual weight should be	o used for
calculating both the toxic dose and the acetylcysteine dose, up to a maximum of 110kg.	ie useu ioi
calculating both the toxic dose and the acetyloysteine dose, up to a maximum of 110kg.	
For pregnant patients the toxic dose in mg/kg should be calculated using the patient's pr	e-nreanancy
weight	c programicy
weight	

This document represents the care expected for a majority of your patients. It is expected that some patients will need care other than that noted. This is referred to as a 'Variance' and should be noted as 'Var' in the appropriate space & explained fully on the 'Varience' sheet, page 11.

Clinicians are free to exercise their own professional judgements as appropriate. However, any alteration to practice noted in this document should be noted as a 'Variance' in notes.

NHS BORDERS		
Patients < 16 years	ADDRESSOGRAPH, or	
INGESTION OF A THERAPEUTIC EXCESS OF		
PARACETAMOL	Name:	
Date:	DoB:	
Dute.	Hospital number:	
Clinical area: ED □ Ward □	CHI:	
Please tick boxes as appropriate and initial/time		
Therapeutic excess (ingestions of a greater than the license	d daily dose AND more than equal to 75mg/kg/24 h	nours for
the treatment pain or fever without self – harm intent	3 3	
In dental patients tooth extraction should not be carried out pr	rior to investigations and treatment (if necessary) du	ue to the
increased risk of bleeding.		
IMMEDIATE ASSESSME	NT AND MANAGEMENT	
Assessment of hepatic injury		
Clinical features of hepatic injury(jaundice or hepatic tenderne	ess)? Yes □	No □
If Yes,		_
START ACETYLCYSTEINE IMMEDIATELY (Refer to the state of the state	- · · · · · · · · · · · · · · · · · · ·	
 Obtain blood samples for paracetamol level, U&Es, L 	FTs, GGT,INR,FBC	
If No,		Initial
ASSESS FOR RISK OF LIVER DAMAGE		& time
Paracetamol ingested in any 24 hour period	mg/kg (see calculation on page 3)	C time
If maximum dose is more than 75mg/kg in any 24 – hour	period	
 Obtain blood samples for paracetamol level, U&Es, \(\) 	√BG, lactate, LFTs,GGT,INR,FBC,	
at least 4 hours after the last ingestion		
If maximum dose is more than licensed 24-hour dose for		
than 75mg/kg/24 hours over the proceeding 2days or m Risk of toxicity is extremely small but consider blood tests fro		
with lactate, LFTs, GGT, INR, FBC at least 4 hours after the		
There is doubt about the doses ingested, OR	idat ingestion especially ii.	
Other factors are present that may increase the r	isk of henatoxixity, such as:	
	henobarbital, phenytoin, rifapacin, St John's Wort	
or other drugs that induce liver enzymes	, , , , , , , , , , , , , , , , , , ,	
 Regular consumption of alcohol in excess of 		
	ders, cystic fibrosis ,HIV, starvation, cachexia	
If maximum dose is consistently less than the licensed 2		
consistently less than 75mg/kg over the preceding 24-ho		
 Blood tests are not needed, and the patient can be (also see 'Subsequent Management & Discharge Ad 		
On receipt of blood results assess risk of hepatotoxicity		_
Clinically significant hepatotoxicity isunlikely if at lea.		
ingestion:	st 4 flours of filore after the last paracetamor	
the paracetamol concentration is less than 10mg.	g/l, AND	
- the ALT is within normal range (50UL), AND	,	
 the INR is 1.3 or less, AND 		
 the patient has no symptoms suggesting liver da 	=	
Acetylcysteine can be discontinued if ALL the above		
If these criteria are met and acetylcysteine has been		
If these criteria are not met start acetylcysteine(r	efer to SNAP dosage on infusion chart	
Assessment of renal function		
If acetylcysteine is not required and the creatinine no Provide the nations with a 'Deficient information cheet'.		
Provide the patient with a 'Patient information sheet'		
 If acetylcysteine is not required and the creatinine is monitoring of renal function and if required, treated or 		
The underlying clinical reason for chronic excess dosage sho	·	-
The anachying chinear reason for chronic excess absage sho	ara armays se considered	
Advanced Nurse Practitioner/ senior medical staff must	review blood results prior to discontinuing ther	anv
Auvanceu Mui se Fractitionen senior medicai stail must	Teview blood results prior to discontinuing there	apy

Advanced Nurse Practitioner/ senior medical staff mus	st review blood results prior to	discontinuing therapy
Results reviewed by	Date	Time
Acetylcysteine discontinued		No □
If acetylcysteine is not indicated or discontinued and further	blood sampling is required, pag	e 9

Patients < 16 years INGESTION OF A THERAPEUTIC EXCESS OF PARACETAMOL	ADDRESSOGRAPH, or
Date:	Name: DoB:
Clinical area: ED □ Ward □	Hospital number: CHI:

Please tick boxes as appropriate and initial/ time in conjunction with inpatient record

Assessment blood results	Repeat blood results (if required)
Date/Time of sample	Date/Time of sample
Urea	Urea
Sodium	Sodium
Potassium	Potassium
Creatinine	Creatinine
Bilirubin	Bilirubin
ALT	ALT
AlkPhos	AlkPhos
GGT	GGT
Albumin	Albumin
Hb	Hb
MCV	MCV
WCC	WCC
Platelets	Platelets
INR	INR
Plasma paracetamol	Plasma paracetamol
concentration	concentration
Athours post ingestion	Athours post ingestion
Glucose	Glucose
рН	pH
Lactate	Lactate
HCO3	HCO3
BE	BE
Other	Other
Initials date/time	Initials date/time

NHS BORDERS

Patients < 16 years INGESTION OF A THERAPEUTIC EXCESS OF	ADDRESSOGRAPH, or
PARACETAMOL Date: Clinical area: ED □ Ward □	Name: DoB: Hospital number: CHI:

REACTION to acetylcysteine				COMPLICATIONS of paracetamol ingestion			
None Flushing Vomiting Rash		Wheeze Hypotension Other Specify		Abnormal liver function Acute kidney injury Hypoglycaemia Acidosis		Encephalopathy Haemorrhage Other Specify	
Date and time of reaction		Initial		Date and time of reaction		Initi	al

MANAGEMENT OF SIDE EFFECTS:

- N-acetylcysteine may cause anaphylactoidreations in 2% of cases with this protocol. Flushing, pruritus, rash, hypotension, angioedema, brochospasm and vomiting are most common
- Reactions can be managed by stopping the infusion. Consider chlorphenamine for flushing/itch, nebulised salbutamol if there is brochospasm and ondansetron if there are GI effects.
- Restart the infusion once the reaction has resolved at half the rate to completion of infusion
- Previous reaction is NOT a contra-indication to N-acetylcysteine and cases should receive treatment if indicated. Reactions are now considerably less common with this protocol compared to standardregimes

Ondansetron oral or IV slow injection (nausea and vomiting) – Age 6 months -16 years				
Body weight	Dose			
Up to 10kg	2mg three times a day			
10 -40kg	4mg three times a day			
41kg and above	8mg three times a day			
Chlorphenamine oral (rash and itch)				
Age	Dose			
1-23 months	1mg twice per day			
2-5 years	1mg 4-6 hourly maximum 6mg per day			
6-11 years	2mg 4-6 hourly maximum 12mg per day			
12-16 years	4mg 4-6 hourly maximum 24mg per day			
Chlorphenamine IV injection (rash or itch)				
Age	Dose			
1-5 months	250 microgrames/kg, maximum 4 times daily			
6 months-5years	2.5mg, maximum four times daily			
6-11 years	5mg, maximum four times daily			
12-16 years	10mg, maximum four times daily			

11113	ONDENS									
	_			AD	DRESS	OGRAPH, or				7
Patients < 16	•					,				
	F A THERAPEUT	TIC EXCESS OF		Na	ame:					
PARACETAMO)L			Do	B:					
Date:				Ho	spital	number:				
Clinical area:	ED □ Wa	rd □		Cł						
		REVIEW OF	TREAT	MENT V	VITH A	CETYLCYS	TEINE			
• 10 h	our bloods: n	ormally 2 hours							Initial/time	ē
	U&Es, LFTs,	FBC, INR &PAR	ACETAMO	OL CON	CENTRA	TION				
• 10 h	our bloods: o	btain usually 2 l	hours befo	ore the	end of 2	2 nd infusion				
 Bloo 	d results docu	umented in tabl	e below							
• Resu	ults reviewed	by Advanced N	urse Prac	titioner	/senior	medical staf	f			
10 hour bloc										
• Crite	eria for DISCO	NTINUING acet	ylcysteine	e after 2	nd infus	sion are:				
	INR 1.3 or	less AND								
	ALT less th	nan 100 U/L AN	D							
	ALT not m	ore than doubl	e the adm	ission m	neasure	ment AND				
	PARACETA	AMOL concentra	ation less	than 20	mg/L					
• Deci	sion to contir	nue or discontin	ue acetyl	cysteine	on pa	ge 8				
• ALL	PATIENT SHO	ULD REMAIN IN	I HOSPITA	AL FOR 2	O HOU	R BLOOD SA	MPLIN	G see page	8	
Blood re	sults									
	<u>Pre</u>	10 hour bloods	s 20 h	our bloo	ds	End of exte	nded	Enc		extended
	Treatment					<u>treatment</u> bloods		trea	tment blo	ods
Notes	*	Blood samples		samples 8		Blood sample			samples	2 hours
	Copy from	2 hours before the end of infusion 2	after th	e end of i	nfusion	hours before		before	e the eduction	end of
	page 6	end of initusion 2	2			infusion	nueu	extern	ueu iiiiusioii	
		Date/time take	n Date/t	ime takei	n	Date/time ta	ken	Date	e/time take	n
		Initial	Initia	l		Initial		Initi	al	
Urea										
Sodium										
Potassium	*			r	_					_
pH/HCO3/BE										
Creatinine	*									
eGFR										
Dilim daile										
Bilirubin										
ALT	*									
ALT Alk. Phos	*									
ALT	*									

*

*

Initial

Continue / stop

Initial

stop

Restart / continue /

Initial

Continue / stop

Initial

Continue / stop

Platelets

Paracetamol

Reviewed by

Decision

INR

NHS BORDERS

Patients < 16 years INGESTION OF A THERAPEUTIC EXCESS OF PARACETAMOL Date: Clinical area: ED Ward	ADDRESSOGRAPH, or Name: DoB: Hospital number: CHI:	
If criteria for discontinuing acetylcysteine at en	d of 2nd infusion are met:	Initial/time
Discontinue acetylcysteine once 2nd infusio		
Acetylcysteine discontinued at		
 The patient should remain in hospital for 	or discharge bloods (20 hour bloods)	
U&Es, LFTs, FBC, INR, -8 h	nours after the acetylcysteine was discontinued	
20 hour bloods due at 20 hour bloods		
If criteria for discontinuing acetylcysteine at en		
Continue acetylcysteine treatment at the dose		
 Obtain 20 hour bloods, 2 hours before the end of 	of the extra bag of acetylcysteine	
 U&Es, LFTs, FBC & INR 		
20 hour bloods due at20 hour bloods.	bloods obtained at	
FOR ALL PATIENTS:	_	
 20 hour bloods documented in table or 	n page 10	
 Results reviewed by Advanced Paedi 	iatric practitioner/senior medical staff	
 20 hour bloods review Extended or restarted acetylcysteine is in INR is greater than 1.3 OR 	ndicated if:	
ALT has more than doubled from admission	on bloods	
ALT is 100 U/L or more		
This applies to both patients who stopped treatment af	ter 2nd infusion AND patients who continued treat	ment after
2 nd infusion		
 If criteria for extended acetylcysteine are not me If further acetylcysteine is not required, but creatinine presentation renal function should be monitored as a 	e is abnormal or is 10% greater than at	
Decision		Initial/time
 If further treatment or blood sampling is not required 		
& Discharge' (page 9)		
 If monitoring of renal function is required, obtain bl team 	lood samples 12 hours later and review by medic □	al
 If extended or restarted acetylcysteine is indicated 	ated follow advice below	
If extended or restarted treatment is	required:	date/time
Continue acetylcysteine at the dose and infusion ra are met.	ate used in the 2^{nd} infusion until parameters below \Box	
 Recheck U&Es, LFTs, FBC and INR every 10 hou before the end of each extended bag). 	urs to assess the course of liver injury (2 hours □	
 Discontinue extended or restarted tr INR 1.3 or less; OR falling towards normal on two con There is no clinical advantage to treating ALT rises af synthetic function) 	nsecutive blood tests, and less than 3.	nepatic
Extended or restarted treatment with acetylcysteine was r If YES, number of extended bags required		date/time
Once treatment with acetylcysteine is discontinued go to	'Subsequent Management & Discharge' (page 9)	1

NHS BORDERS Patients < 16 years ADDRESSOGRAPH, or INGESTION OF A THERAPEUTIC EXCESS OF **PARACETAMOL** Name: Date: DoB: Hospital number: Clinical area: ED □ Ward □ CHI: **SUBSEQUENT MANAGEMENT & DISCHARGE** Initial/time Criteria for discharge Treatment with acetylcysteine tolerated N/A □ Yes □ No □ Patient eating and drinking. Yes □ No □

Seen by CAMHS/Psychiatry team member N/A □ Yes □ No□ Comment..... Initial/time Treatment complete N/A □ Yes □ Discharge advice given, including paracetamol patient discharge sheet (available on TOXBASE[®]) □ Comment..... Left department Date...... Time...... Time Initial/time Follow-up Has follow-up been arranged? N/A □ Yes □ No □ Comment..... Medical follow-up arrangements are not normally required if blood results are within acceptable range Notes

VARIANCES: all staff to identify & record variances. Types of Variance - break down into types: A - Patient/Relative, B - Clinician, C - Hospital System, D - Community/External. **Record of Variance** Time **Description of issue** Reason Action Initials Var. Date code **EXAMPLE** Reaction to Infusion stopped for 30 minutes. BS 00.15 Flushing Α 28.09.15 acetylcysteine Chlorphenamine administered